X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
Rhea-AI Summary
X4 Pharmaceuticals (NASDAQ: XFOR) said management will join a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 at 10:00 a.m. ET in Miami. A live and archived webcast will be available on the company’s Investors site under Events and Presentations.
Positive
- None.
Negative
- None.
News Market Reaction – XFOR
In the Mar 4 session, XFOR gained 5.11%, reflecting a notable positive market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 27 | Regulatory opinion | Positive | +5.8% | CHMP positive opinion recommending EU approval of mavorixafor for WHIM. |
| Feb 03 | Conference participation | Neutral | +0.5% | Announcement of fireside chat and meetings at Guggenheim biotech summit. |
| Feb 02 | Inducement grants | Neutral | +0.5% | Inducement stock options to new employees under equity incentive plan. |
| Nov 05 | Conference participation | Neutral | -1.3% | Participation in Guggenheim healthcare innovation conference with fireside chat. |
| Nov 05 | Earnings and update | Negative | -10.6% | Q3 2025 loss, large financings, workforce reduction, and strategy refocus. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, from major regulatory wins to conferences and financings, has generally seen price moves that align with the underlying news tone.
Over the past several months, X4 has combined clinical and regulatory progress with active capital markets activity. A CHMP positive opinion for mavorixafor in WHIM syndrome drove a +5.85% move, while multiple conference appearances and inducement grants produced modest reactions. Earlier, Q3 2025 results highlighted the 4WARD Phase 3 trial, substantial financings totaling $240.3M, and restructuring actions including a 50% workforce reduction, which coincided with a -10.58% price reaction. Today’s conference participation fits this pattern of ongoing investor outreach.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management team will participate in a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 at 10:00 a.m. ET in Miami, FL.
A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations.
About X4 Pharmaceuticals
X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is commercially available in the U.S. as XOLREMDI® in its first indication. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.
X4 Investor Contact:
Remy Bernarda
Jenny Kobin
IR Advisory Solutions
ir@x4pharma.com
Source: X4 Pharmaceuticals, Inc.
